The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...
Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...
Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...
Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...
Novartis said Friday that it expects core operating profit--one of its preferred metrics, which strips out exceptional items--for 2025 to grow in the high-single-digit to low-double-digit range and ...
Novartis expects profit and sales to grow further this year after beating analysts' expectations in the fourth quarter, boosted by revenue from its key drugs.
Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast.
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...
Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...
Novartis is the latest drugmaker to sue the government for allegedly rejecting its proposed model to distribute federal drug discounts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback